Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Clinical Trial
NCT03906071Last updated: 12/4/2025
MRTX
Mirati Therapeutics, Inc.
